ClinicalTrials.gg
TerminatedNCT01082965Updated Sep 12, 2013Results posted

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

An interventional study of Donepezil and Placebo in Alzheimer's Disease, sponsored by Pfizer. Terminated at 8 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-09-12.

Sponsored by Pfizer · Not applicable, Interventional, and Basic science

Why this study was terminated
The study was terminated because of slow enrollment. The decision to terminate the trial was not based on any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
52nd of 58
18 · median 79
Started
2010
with 1 other
No phase
6 of 60
none open now
Registered
31st of 60
by date
Lead sponsor
4 of 60
Pfizer

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 52nd largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2010, is one of 6 with no phase, and was the 31st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in memory.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • ASL MRI
  • perfusion
  • cognition
  • donepezil
  • alzheimer's disease
  • translational medicine
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects and caregivers must provide written and be willing to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.
  • AD: Diagnostic evidence of probable AD consistent with , Fourth Edition (DSM-IV) and National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria met by the site Physician at the time of the Screening visit. This evidence must be fully documented in the participant's file prior to the Baseline Visit.
  • For amnestic Mild Cognitive Impairment (MCI): A Clinical Dementia Rating (CDR) of 0.5 (with memory box score of at least 0.5) and a memory complaint that is objectively verified using a test of episodic memory: Delayed recall from one paragraph of the Wechsler Logical Memory scale (cutoff scores by education - maximum score of 25).
  • Less than or equal to 8 for 16 or more years of education; Less than or equal to 4 for 8-15 years of education; Less than or equal to 2 for 0-7 years of education.
  • (MMSE) score of 21-30
  • Male and female subjects of non (or using appropriate measures) who are at least 50 years of age.
  • In generally good health, in the opinion of the Principal Investigator (PI), based on medical history, (BMI), physical examination, vital signs, 12-lead , and laboratory values, including hematology and chemistry values.
  • No known genetic AD causes for early onset memory impairment (e.g., presenilin mutation), participants from a family with known autosomal dominant AD associated with mutations in APP, PS1, or PS2 genes or strongly suspected, but not yet identified mutations in APP, PS1 or PS2 genes or Down's syndrome are not eligible to enroll. Individuals from families with late onset AD with 2 or more affected family members may participate.

Type II diabetic subjects may be included provided that their disease and serum glucose values are controlled and being actively managed, as assessed by the PI using a fasting blood sugar and/or HgbA1C (per the PI's medical judgment in consultation with the Sponsor).

  • Rosen-Modified Hachinski Ischemia Score less than or equal to 4.

Exclusion Criteria:

  • Diagnosis or history of other possible cause for or significant contributor to dementia, including but not limited to other neurodegenerative disorders (eg, frontotemporal dementia, Lewy body disease, vascular dementia), vitamin B12 deficiency (reflex Methylmalonic Acid (MMA) and folate if B12 is low), untreated thyroid disease, syphilis, alcoholism, severe or recurrent head injury that is to the disease under study, or onset of dementia following heart surgery or cardiac arrest.
  • Diagnosis or history of cerebrovascular disease (eg, stroke, ), severe carotid stenosis, cerebral hemorrhage, intracranial tumor, subarachnoid hemorrhage, or subdural hematoma that could contribute to the subject's current cognitive or functional status, impair ability to fully participate in the trial or that may impact status during the one week study.
  • Specific exclusionary brain MRI findings identified prior to study or at baseline as determined by the investigator that could either contribute to the subject's current cognitive or functional decline impair ability to fully participate in the trial or that may impact status during the trial:
  • History of cancer within the last year (except for cutaneous basal cell, squamous cell cancer resolved by excision, colon polyp resolved by excision, or non-progressive prostate cancer per investigator's judgment).
  • History of clinically significant cardiovascular or renal events.
  • Subjects with uncontrolled hypertension even with therapeutic intervention
  • History of clinically significant (as determined by the PI in consultation with the Sponsor) syncope, seizure, head trauma, or clinically significant unexplained loss of consciousness within the last 5 years.
  • A diagnosis of major depressive disorder or other psychiatric illness as the primary diagnosis per the DSM-IV text revision (TR) criteria per the investigator's judgment.
  • History of schizophrenia, bipolar disorder, or other severe mental illness.
  • Known history of alcohol or drug abuse (as defined by the DSM-IV-TR) within 5 years prior to dosing or a positive result regarding use of illicit drugs on the drug screening test.
  • History of clinically significant symptoms of pulmonary disease that requires treatment (eg. asthma, , or other chronic respiratory conditions).
  • Known positive (HIV) status.
  • Unwilling or unable to comply with the Life Style guidelines described in this protocol.

Exclusions Related to Medications or Procedures

  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) of Study Day 1.
  • Use of tobacco- or nicotine-containing products within three months of study Day 1.

Use of medication(s) for cognitive enhancement ≤ 90 days before the first dose of study medication.

  • Prescription: including but not limited to donepezil, galantamine, rivastigmine, tacrine, memantine, Axona™;
  • Reason for stoppage of donepezil may not be related to tolerability issues or to gain entry in this study.
  • Non-prescription treatments for cognitive enhancement.

    • Subjects with either non-removable ferromagnetic implants (such as cardiac pacemaker), aneurysm clips or other foreign bodies that would contraindicate a brain MRI scan.
    • A clinically significant (as determined by the PI) abnormality in the 12-lead ECG, including complete heart block, bradycardia (heart rate \<40 beats/minute), sinus pauses >2 seconds, second or third degree heart block, >450 or other abnormalities judged clinically significant by the PI.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Treatment

    Drug: Donepezil

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 5 mg tablets once daily for 7 days and then 10mg on 8th day

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 1

    Posterior cingulate cortex perfusion was measured by arterial spin labeling (ASL). ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.

    Time frame: Baseline, 4 hours post-dose on Day 1

  2. Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 0 on Day 8

    Posterior cingulate cortex perfusion was measured by ASL. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.

    Time frame: Baseline, 1 minute post-dose (Hour 0) on Day 8

  3. Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 8

    Posterior cingulate cortex perfusion was measured by ASL. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.

    Time frame: Baseline, 4 hours post-dose on Day 8

Secondary outcomes

  1. Change From Baseline in Arterial Spin Label (ASL) Perfusion at Hour 4 on Day 1 and at Hour 0, 4 on Day 8

    Perfusion in anterior cingulate cortex, medial prefrontal cortex, precuneus, inferior parietal cortex and other regions of interest (whole brain gray, superior, medial and inferior temporal cortex; inferior and superior prefrontal cortex; insula, amygdala, thalamus, basal ganglia, hippocampus, Landau) was measured by ASL technique. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for relative perfusion rate. Relative perfusion rate is defined as the absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point.

    Time frame: Baseline, 4 hours post-dose on Day 1, 1 minute post-dose (Hour 0), 4 hours post-dose on Day 8

  2. Change From Baseline in CogState Continuous Paired Associate Learning (CPAL) at Hour 5 on Day 1 and at Hour 1, 5 on Day 8

    CPAL: a cognitive test which assessed visual episodic learning. Participant was to learn and remember picture locations on the screen and was to tap the target on the central location to begin. As each picture was revealed, the participant was to remember where the picture was located and tap that location. After 4 pictures were placed correctly, second round started. In second round pictures remain in the same locations, but their order of presentation in the center of the screen was different to that of the first round (randomized). The same process was repeated for round 3 and round 4. The outcome was the number of errors made in correctly placing each of the 4 patterns in their location 4 times.

    Time frame: Baseline, 5 hours post-dose on Day 1; 1, 5 hours post-dose on Day 8

  3. Change From Baseline in Rey Auditory Verbal Learning Test (RAVLT): Immediate and Delayed Recall at Hour 5 on Day 8

    RAVLT, in immediate recall (IR) list of 15 words (list A) was read aloud to participant 5 times followed by a test of spontaneous retrieval (A1 to A5). After fifth attempt a list of interference, comprising 15 words (list B) was read to participant followed by its retrieval (B1). After attempt B1 examiner asked individual to recall words from list A, without reading it again (A6). Score range: 0-105, higher scores=less impairment. Delayed recall (DR):after a 20-minute interval examiner asked individual to remember words from list A without reading this list; in recognition performance a list comprising 15 words from list A, 15 words from list B, 20 distracting words (similar to words in list A, B) was read to individual. Upon each word read aloud, individual asked to indicate if it belonged to list A, or not. Score range: 0-30, higher scores=less impairment.

    Time frame: Baseline, 5 hours post-dose on Day 8

  4. Change From Baseline in CogState Test Battery at Hour 5 on Day 1 and at Hour 0, 5 on Day 8

    Computerized test battery used to assess detection and identification task. CogState detection task: a measure of simple reaction time, provided valid assessment of psychomotor function. Participants were required to press a "YES" response key as soon as they detected an event (a card turning face up presented in center of the computer screen). The software measured the response time to detect each event. CogState identification task: measure of choice reaction time, provided a valid assessment of visual attention. Participants were required to decide "YES" or "NO" as to whether the event met a predefined and unchanging criterion (is the color of the card red?) while the event (a card turning face up) occurred in the center of the computer screen. The software measured the speed and accuracy of each response.

    Time frame: Baseline, 5 hours post-dose on Day 1; 1, 5 hours post-dose on Day 8

07

Results

Posted Sep 12, 2013
Limitations and caveats
The study was terminated because of the prohibitively low recruitment rate and the reassessment of the Neuroscience Research Unit portfolio. The decision to terminate the study was not based on any safety or efficacy concerns.

Participant flow

Participant flow — Overall Study
MilestoneDonepezilPlacebo
Started108
Completed96
Not completed12
Withdrew: Protocol violation01
Withdrew: Other11

Outcome measures

PrimaryChange From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 1

Posterior cingulate cortex perfusion was measured by arterial spin labeling (ASL). ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.

Time frame:
Baseline, 4 hours post-dose on Day 1
Reported as:
Mean · ratio
Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 1
ratioDonepezilPlacebo
Baseline1.243 ± 0.25861.564 ± 0.2494
Change at Hour 4 on Day 10.156 ± 0.5178-0.017 ± 0.3810
Statistical analysis
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.9742 (Statistical significance level alpha (2-sided) was 0.05.) · Leasts square (ls) mean: -0.01 · 95% CI -0.60 to 0.58
PrimaryChange From Baseline in Posterior Cingulate Cortex Perfusion at Hour 0 on Day 8

Posterior cingulate cortex perfusion was measured by ASL. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.

Time frame:
Baseline, 1 minute post-dose (Hour 0) on Day 8
Reported as:
Mean · ratio
Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 0 on Day 8
ratioDonepezilPlacebo
Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 0 on Day 80.263 ± 0.48720.093 ± 0.5624
Statistical analysis
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.9638 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.01 · 95% CI -0.51 to 0.49
PrimaryChange From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 8

Posterior cingulate cortex perfusion was measured by ASL. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.

Time frame:
Baseline, 4 hours post-dose on Day 8
Reported as:
Mean · ratio
Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 8
ratioDonepezilPlacebo
Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 8-0.008 ± 0.2506-0.004 ± 0.3948
Statistical analysis
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.2548 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.19 · 95% CI -0.53 to 0.16
SecondaryChange From Baseline in Arterial Spin Label (ASL) Perfusion at Hour 4 on Day 1 and at Hour 0, 4 on Day 8

Perfusion in anterior cingulate cortex, medial prefrontal cortex, precuneus, inferior parietal cortex and other regions of interest (whole brain gray, superior, medial and inferior temporal cortex; inferior and superior prefrontal cortex; insula, amygdala, thalamus, basal ganglia, hippocampus, Landau) was measured by ASL technique. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for relative perfusion rate. Relative perfusion rate is defined as the absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point.

Time frame:
Baseline, 4 hours post-dose on Day 1, 1 minute post-dose (Hour 0), 4 hours post-dose on Day 8
Reported as:
Mean · ratio
Change From Baseline in Arterial Spin Label (ASL) Perfusion at Hour 4 on Day 1 and at Hour 0, 4 on Day 8
ratioDonepezilPlacebo
Baseline: Whole Brain Gray1.486 ± 0.12151.500 ± 0.0869
Baseline: Superior Temporal Cortex1.749 ± 0.27741.773 ± 0.1732
Baseline: Medial Temporal Cortex1.753 ± 0.31861.718 ± 0.2778
Baseline: Inferior Temporal Cortex1.260 ± 0.46341.173 ± 0.4024
Baseline: Medial Prefrontal Cortex1.488 ± 0.18301.709 ± 0.1441
Baseline: Inferior Prefrontal Cortex1.381 ± 0.22051.486 ± 0.1673
Baseline: Superior Prefrontal Cortex1.308 ± 0.12361.443 ± 0.2046
Baseline: Inferior Parietal Cortex1.610 ± 0.28241.714 ± 0.1628
Baseline: Insula1.390 ± 0.17851.533 ± 0.2130
Baseline: Precuneus1.357 ± 0.19041.505 ± 0.2781
Baseline: Anterior Cingulate Cortex1.236 ± 0.22651.442 ± 0.1753
Baseline: Amygdala1.067 ± 0.30251.256 ± 0.2966
Baseline: Thalamus1.417 ± 0.48861.468 ± 0.3061
Baseline: Basal Ganglia1.120 ± 0.27811.241 ± 0.2461
Baseline: Hippocampus1.327 ± 0.27261.389 ± 0.1229
Baseline: Landau1.916 ± 0.37532.025 ± 0.0940
Change at Hour 4 on Day 1: Whole Brain Gray0.018 ± 0.23090.050 ± 0.1010
Change at Hour 4 on Day 1:Superior Temporal Cortex0.031 ± 0.34300.023 ± 0.3002
Change at Hour 4 on Day 1: Medial Temporal Cortex-0.066 ± 0.5297-0.006 ± 0.2549
Change at Hour 4 on Day 1:Inferior Temporal Cortex-0.052 ± 0.62890.090 ± 0.2734
Change at Hour 4 on Day 1:Medial Prefrontal Cortex0.035 ± 0.2704-0.164 ± 0.2054
Change at Hour4 on Day1:Inferior Prefrontal Cortex0.143 ± 0.1987-0.061 ± 0.2299
Change at Hour4 on Day1:Superior Prefrontal Cortex0.064 ± 0.2702-0.062 ± 0.2361
Change at Hour 4 on Day 1:Inferior Parietal Cortex-0.054 ± 0.2411-0.016 ± 0.1848
Change at Hour 4 on Day 1: Insula0.154 ± 0.28130.096 ± 0.3276
Change at Hour 4 on Day 1: Precuneus-0.024 ± 0.30020.053 ± 0.2952
Change at Hour 4 on Day1:Anterior Cingulate Cortex0.118 ± 0.21680.173 ± 0.2709
Change at Hour 4 on Day 1: Amygdala0.187 ± 0.55040.175 ± 0.3785
Change at Hour 4 on Day 1: Thalamus0.244 ± 0.5697-0.038 ± 0.2209
Change at Hour 4 on Day 1: Basal Ganglia0.292 ± 0.45570.014 ± 0.1761
Change at Hour 4 on Day 1: Hippocampus0.128 ± 0.21150.036 ± 0.2915
Change at Hour 4 on Day 1: Landau-0.051 ± 0.3923-0.033 ± 0.1952
Change at Hour 0 on Day 8: Whole Brain Gray0.058 ± 0.10240.028 ± 0.1569
Change at Hour 0 on Day 8:Superior Temporal Cortex0.051 ± 0.26780.038 ± 0.3095
Change at Hour 0 on Day 8: Medial Temporal Cortex-0.015 ± 0.3095-0.052 ± 0.2575
Change at Hour 0 on Day 8:Inferior Temporal Cortex0.084 ± 0.6856-0.012 ± 0.3842
Change at Hour 0 on Day 8:Medial Prefrontal Cortex-0.198 ± 0.4168-0.173 ± 0.3050
Change at Hour0 on Day8:Inferior Prefrontal Cortex0.043 ± 0.33530.010 ± 0.2188
Change at Hour0 on Day8:Superior Prefrontal Cortex-0.152 ± 0.3120-0.019 ± 0.2863
Change at Hour 0 on Day 8:Inferior Parietal Cortex0.005 ± 0.5185-0.106 ± 0.2009
Change at Hour 0 on Day 8: Insula0.103 ± 0.26790.154 ± 0.1816
Change at Hour 0 on Day 8: Precuneus0.055 ± 0.40650.059 ± 0.3475
Change at Hour 0 on Day8:Anterior Cingulate Cortex0.279 ± 0.44240.167 ± 0.3681
Change at Hour 0 on Day 8: Amygdala0.170 ± 0.53880.083 ± 0.4233
Change at Hour 0 on Day 8: Thalamus0.195 ± 0.6486-0.063 ± 0.4992
Change at Hour 0 on Day 8: Basal Ganglia0.243 ± 0.39250.040 ± 0.3106
Change at Hour 0 on Day 8: Hippocampus0.170 ± 0.28320.047 ± 0.2551
Change at Hour 0 on Day 8: Landau-0.030 ± 0.5354-0.105 ± 0.2642
Change at Hour 4 on Day 8: Whole Brain Gray0.010 ± 0.1286-0.022 ± 0.0945
Change at Hour 4 on Day 8:Superior Temporal Cortex0.126 ± 0.3065-0.037 ± 0.1319
Change at Hour 4 on Day 8: Medial Temporal Cortex-0.103 ± 0.2852-0.110 ± 0.2551
Change at Hour 4 on Day 8:Inferior Temporal Cortex-0.194 ± 0.5644-0.102 ± 0.3114
Change at Hour 4 on Day 8:Medial Prefrontal Cortex0.111 ± 0.3606-0.038 ± 0.2262
Change at Hour4 on Day8:Inferior Prefrontal Cortex-0.031 ± 0.2477-0.001 ± 0.2342
Change at Hour4 on Day8:Superior Prefrontal Cortex0.225 ± 0.3460-0.007 ± 0.1348
Change at Hour 4 on Day 8:Inferior Parietal Cortex-0.175 ± 0.4557-0.017 ± 0.1560
Change at Hour 4 on Day 8: Insula0.148 ± 0.14770.078 ± 0.2317
Change at Hour 4 on Day 8: Precuneus-0.110 ± 0.38460.074 ± 0.3035
Change at Hour 4 on Day8:Anterior Cingulate Cortex0.180 ± 0.29390.062 ± 0.1423
Change at Hour 4 on Day 8: Amygdala0.097 ± 0.49840.019 ± 0.3100
Change at Hour 4 on Day 8: Thalamus-0.124 ± 0.5028-0.077 ± 0.5330
Change at Hour 4 on Day 8: Basal Ganglia0.084 ± 0.3393-0.066 ± 0.2787
Change at Hour 4 on Day 8: Hippocampus0.041 ± 0.27700.017 ± 0.1225
Change at Hour 4 on Day 8: Landau-0.208 ± 0.31520.008 ± 0.1418
Statistical analysis
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.6316 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.03 · 95% CI -0.18 to 0.12
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.6256 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.03 · 95% CI -0.12 to 0.19
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.5847 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.03 · 95% CI -0.12 to 0.19
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.1555 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.19 · 95% CI -0.46 to 0.09
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.2416 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.18 · 95% CI -0.51 to 0.14
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.8070 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.03 · 95% CI -0.33 to 0.26
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.6828 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.08 · 95% CI -0.59 to 0.43
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.8987 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.01 · 95% CI -0.26 to 0.29
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.8922 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.02 · 95% CI -0.28 to 0.25
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.7555 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.07 · 95% CI -0.39 to 0.52
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.1928 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.30 · 95% CI -0.18 to 0.79
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.4946 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.12 · 95% CI -0.26 to 0.49
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.7029 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.08 · 95% CI -0.56 to 0.40
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.1085 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.30 · 95% CI -0.68 to 0.08
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.3588 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.13 · 95% CI -0.44 to 0.18
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.3053 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.17 · 95% CI -0.20 to 0.53
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.9861 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.00 · 95% CI -0.36 to 0.36
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.6558 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.07 · 95% CI -0.41 to 0.28
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.9471 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.01 · 95% CI -0.53 to 0.51
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.2136 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.27 · 95% CI -0.77 to 0.23
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.6435 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.10 · 95% CI -0.47 to 0.67
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.0659 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.20 · 95% CI -0.41 to 0.02
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.7687 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.05 · 95% CI -0.41 to 0.31
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.1061 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.32 · 95% CI -0.73 to 0.10
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.3925 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.11 · 95% CI -0.41 to 0.19
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.1991 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.22 · 95% CI -0.58 to 0.14
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.5176 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.10 · 95% CI -0.45 to 0.24
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.3140 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.16 · 95% CI -0.50 to 0.18
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.6348 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.08 · 95% CI -0.46 to 0.29
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.1491 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.26 · 95% CI -0.64 to 0.12
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.4226 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.16 · 95% CI -0.59 to 0.27
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.9778 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.01 · 95% CI -0.49 to 0.50
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.9456 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.01 · 95% CI -0.40 to 0.43
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.2299 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.20 · 95% CI -0.55 to 0.15
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.5069 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.13 · 95% CI -0.54 to 0.28
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.3524 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.14 · 95% CI -0.45 to 0.17
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.4182 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.34 · 95% CI -0.80 to 1.47
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.3630 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.31 · 95% CI -0.42 to 1.04
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.9837 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.01 · 95% CI -0.73 to 0.74
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.0974 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.19 · 95% CI -0.04 to 0.42
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.1246 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.11 · 95% CI -0.04 to 0.27
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.6190 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.06 · 95% CI -0.20 to 0.32
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.6350 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.07 · 95% CI -0.39 to 0.25
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.8205 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.04 · 95% CI -0.40 to 0.32
  • Donepezil · Mixed Models Analysis · p = 0.2959 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.15 · 95% CI -0.42 to 0.14
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.5520 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.12 · 95% CI -0.56 to 0.32
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.9046 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.03 · 95% CI -0.50 to 0.45
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.0402 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -0.32 · 95% CI -0.62 to -0.02
SecondaryChange From Baseline in CogState Continuous Paired Associate Learning (CPAL) at Hour 5 on Day 1 and at Hour 1, 5 on Day 8

CPAL: a cognitive test which assessed visual episodic learning. Participant was to learn and remember picture locations on the screen and was to tap the target on the central location to begin. As each picture was revealed, the participant was to remember where the picture was located and tap that location. After 4 pictures were placed correctly, second round started. In second round pictures remain in the same locations, but their order of presentation in the center of the screen was different to that of the first round (randomized). The same process was repeated for round 3 and round 4. The outcome was the number of errors made in correctly placing each of the 4 patterns in their location 4 times.

Time frame:
Baseline, 5 hours post-dose on Day 1; 1, 5 hours post-dose on Day 8
Reported as:
Mean · errors
Change From Baseline in CogState Continuous Paired Associate Learning (CPAL) at Hour 5 on Day 1 and at Hour 1, 5 on Day 8
errorsDonepezilPlacebo
Baseline (n=9, 8)46.222 ± 28.743637.625 ± 17.8641
Change at Hour 5 on Day 1 (n=9, 8)4.333 ± 24.0936-2.625 ± 28.9084
Change at Hour 1 on Day 8 (n=9, 6)-5.444 ± 31.9653-15.833 ± 15.8293
Change at Hour 5 on Day 8 (n=9, 6)2.000 ± 16.3325-8.000 ± 17.4126
Statistical analysis
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.6880 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 5.00 · 95% CI -21.82 to 31.82
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.3157 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 9.79 · 95% CI -11.30 to 30.87
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.3228 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 9.86 · 95% CI -13.56 to 33.28
SecondaryChange From Baseline in Rey Auditory Verbal Learning Test (RAVLT): Immediate and Delayed Recall at Hour 5 on Day 8

RAVLT, in immediate recall (IR) list of 15 words (list A) was read aloud to participant 5 times followed by a test of spontaneous retrieval (A1 to A5). After fifth attempt a list of interference, comprising 15 words (list B) was read to participant followed by its retrieval (B1). After attempt B1 examiner asked individual to recall words from list A, without reading it again (A6). Score range: 0-105, higher scores=less impairment. Delayed recall (DR):after a 20-minute interval examiner asked individual to remember words from list A without reading this list; in recognition performance a list comprising 15 words from list A, 15 words from list B, 20 distracting words (similar to words in list A, B) was read to individual. Upon each word read aloud, individual asked to indicate if it belonged to list A, or not. Score range: 0-30, higher scores=less impairment.

Time frame:
Baseline, 5 hours post-dose on Day 8
Reported as:
Mean · units on a scale
Change From Baseline in Rey Auditory Verbal Learning Test (RAVLT): Immediate and Delayed Recall at Hour 5 on Day 8
units on a scaleDonepezilPlacebo
Baseline: Total IR (n=9, 8)25.667 ± 7.314427.000 ± 9.3960
Baseline: Total DR (n=9, 8)2.444 ± 2.35112.375 ± 2.1998
Change at Hour 5 on Day 8:Total IR (n=9, 6)3.333 ± 4.18335.667 ± 4.3665
Change at Hour 5 on Day 8: Total DR (n=9, 6)0.444 ± 1.94370.333 ± 3.0111
Statistical analysis
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.2540 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: -4.39 · 95% CI -12.90 to 4.12
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.7684 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.60 · 95% CI -4.17 to 5.37
SecondaryChange From Baseline in CogState Test Battery at Hour 5 on Day 1 and at Hour 0, 5 on Day 8

Computerized test battery used to assess detection and identification task. CogState detection task: a measure of simple reaction time, provided valid assessment of psychomotor function. Participants were required to press a "YES" response key as soon as they detected an event (a card turning face up presented in center of the computer screen). The software measured the response time to detect each event. CogState identification task: measure of choice reaction time, provided a valid assessment of visual attention. Participants were required to decide "YES" or "NO" as to whether the event met a predefined and unchanging criterion (is the color of the card red?) while the event (a card turning face up) occurred in the center of the computer screen. The software measured the speed and accuracy of each response.

Time frame:
Baseline, 5 hours post-dose on Day 1; 1, 5 hours post-dose on Day 8
Reported as:
Mean · log10 milliseconds
Change From Baseline in CogState Test Battery at Hour 5 on Day 1 and at Hour 0, 5 on Day 8
log10 millisecondsDonepezilPlacebo
Baseline: Detection Task (n=9, 8)2.572 ± 0.11922.542 ± 0.0953
Baseline: Identification Task (n=9, 8)2.708 ± 0.06352.727 ± 0.0540
Change at Hour 5 on Day 1: Detection Task (n=9, 8)0.002 ± 0.09310.024 ± 0.0706
Change at Hour5 on Day1:Identification Task(n=9,8)0.020 ± 0.03550.012 ± 0.0371
Change at Hour 0 on Day 8: Detection Task (n=9, 6)0.004 ± 0.1184-0.032 ± 0.0512
Change at Hour0 on Day8:Identification Task(n=9,6)0.005 ± 0.06300.004 ± 0.0493
Change at Hour 5 on Day 8: Detection Task (n=9, 6)-0.005 ± 0.10010.004 ± 0.0508
Change at Hour5 on Day8:Identification Task(n=9,6)0.034 ± 0.07820.004 ± 0.0625
Statistical analysis
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.4940 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.04 · 95% CI -0.09 to 0.17
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.1031 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.10 · 95% CI -0.02 to 0.22
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.3277 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.05 · 95% CI -0.06 to 0.16
  • Donepezil · Mixed Models Analysis · p = 0.6585 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.01 · 95% CI -0.05 to 0.08
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.8863 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.00 · 95% CI -0.07 to 0.08
  • Donepezil vs Placebo · Mixed Models Analysis · p = 0.4388 (Statistical significance level alpha (2-sided) was 0.05.) · Ls mean difference: 0.04 · 95% CI -0.06 to 0.13

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil—0/10 (0%)3/10 (30%)
Placebo—0/8 (0%)2/8 (25%)
Most frequent other events
Most frequent other events
EventDonepezilPlacebo
DiarrhoeaGastrointestinal disorders1/101/8
FatigueGeneral disorders0/101/8
ExcoriationInjury, poisoning and procedural complications0/101/8
Sensory disturbanceNervous system disorders0/101/8
Abdominal discomfortGastrointestinal disorders1/100/8
AstheniaGeneral disorders1/100/8

Baseline characteristics

Age Continuous
Age Continuous(years)DonepezilPlaceboTotal
Mean74.7 ± 9.670.6 ± 6.972.9 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)DonepezilPlaceboTotal
Female5611
Male527
08

Study locations

8 sites
  • Pfizer Investigational Site
    San Francisco, California 94122, United States
  • Pfizer Investigational Site
    San Francisco, California 94143, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21224, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21287, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63108, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63110, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19446, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2010
First posted
Mar 9, 2010
Start
Jul 2010
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Sep 12, 2013
Last update
Sep 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01082965
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 9, 2010
Start date
Jul 2010
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Sep 12, 2013
Last update
Sep 12, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion